Details for Patent: 8,573,209

✉ Email this page to a colleague

Which drugs does patent 8,573,209 protect, and when does it expire?

Patent 8,573,209 protects INOMAX and is included in one NDA.

Protection for INOMAX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-four patent family members in thirteen countries.

Summary for Patent: 8,573,209

Title:	Gas delivery device and system
Abstract:	A gas delivery system including a gas delivery device (100), a control module (200) and a gas delivery mechanism is described. An exemplary gas delivery device includes a valve (107) assembly with a valve and circuit including a memory (134), a processor (122) and a transceiver (120) in communication with the memory. The memory may include gas data such as gas identification, gas expiration and gas concentration. The transceiver on the circuit of the valve assembly may send wireless optical line-of-sight signals to communicate the gas data to a control module. Exemplary gas delivery mechanisms include a ventilator (400) and a breathing circuit (410). Methods of administering gas are also described.
Inventor(s):	Bathe; Duncan P. (Fitchburg, WI), Klaus; John (Cottage Grove, WI), Christensen; David (Cambridge, WI)
Assignee:	INO Therapeutics LLC (Hampton, NJ)
Application Number:	13/509,873
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,573,209
Patent Claim Types: see list of patent claims	Delivery; Device;

Drugs Protected by US Patent 8,573,209

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mallinckrodt Hosp	INOMAX	nitric oxide	GAS;INHALATION	020845-002	Dec 23, 1999		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up			Y		⤷ Sign Up
Mallinckrodt Hosp	INOMAX	nitric oxide	GAS;INHALATION	020845-003	Dec 23, 1999	AA	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up			Y		⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 8,573,209

PCT Information
PCT Filed	January 06, 2011	PCT Application Number:	PCT/US2011/020319
PCT Publication Date:	July 12, 2012	PCT Publication Number:	WO2012/094008

International Family Members for US Patent 8,573,209

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2011328891	⤷ Sign Up
Australia	2013257484	⤷ Sign Up
Australia	2015200792	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.